Xellera Therapeutics is a leading CDMO dedicated to Cell and Gene Therapy (CGT) and Advanced Therapy Products (ATP), delivering end-to-end GMP manufacturing solutions. The company supports every stage of product development, ensuring quality, compliance, and timely scale-up. With advanced infrastructure and specialized expertise, Xellera helps innovators streamline production, reduce development risks, and accelerate the path to market for breakthrough therapeutic products.

